Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Fig. 3

Representative microphotographs of immunohistochemical staining for F4/80 in liver sections (a) and percentage in area of positive immunostaining for F4/80 in the five groups (b). Normalized mRNA expression of F4/80 the liver of the five groups (c). Data are mean ± SE. *P < 0.05, ‡P < 0.001 vs. control; §P < 0.05, ¶P < 0.001 vs. vehicle

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us